Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253189 | 0.83 | PTGS2 (0.67) | PTGS2PTGS1PDPK1CA1CA2 | |
| SCHEMBL4245873 | 0.82 | EPHX2 (0.63) | PTGS2HSP90AA1EPHX2 | |
| SCHEMBL4253931 | 0.81 | PTGS2 (0.66) | PTGS2NR3C2PTGS1PDPK1CA1 | |
| SCHEMBL4247404 | 0.81 | PTGS2 (0.58) | PTGS2NR3C2PTGS1EPHX2 | |
| SCHEMBL4251818 | 0.80 | PTGS2 (0.69) | PTGS2NR3C2PTGS1PDPK1EPHX2 | |
| SCHEMBL7319101 | 0.79 | PTGS2 (0.74) | PTGS2PTGS1PDPK1CA1CA2 | |
| SCHEMBL4247407 | 0.79 | EPHX2 (0.65) | PTGS2NR3C2EPHX2 | |
| SCHEMBL4251821 | 0.78 | EPHX2 (0.72) | PTGS2NR3C2PTGS1EPHX2 | |
| SCHEMBL6339092 | 0.78 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CA1CA2 | |
| SCHEMBL4248391 | 0.77 | PTGS2 (0.70) | PTGS2PTGS1PDPK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| EP-1960367-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007067836-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | PTGS2 158/4885NR3C2 2044/4885HSP90AA1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.